Charles Schwab
BCAB icon

Charles Schwab’s BioAtla BCAB Stock Holding History

Charles Schwab’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,391
Closed -$411K – 3626
2024
Q1 		$411K Hold
2,391
– – ﹤0.01% 3096
2023
Q4 		$294K Hold
2,391
– – ﹤0.01% 3224
2023
Q3 		$203K Hold
2,391
– – ﹤0.01% 3286
2023
Q2 		$359K Buy
2,391
+2,022
+548% +$348K ﹤0.01% 3189
2023
Q1 		$49.4K Hold
369
– – ﹤0.01% 3348
2022
Q4 		$152K Buy
369
+108
+41% +$44.8K ﹤0.01% 3224
2022
Q3 		$101K Sell
261
-1,528
-85% -$500K ﹤0.01% 3223
2022
Q2 		$255K Sell
1,789
-332
-16% -$52.8K ﹤0.01% 3212
2022
Q1 		$531K Sell
2,121
-250
-11% -$105K ﹤0.01% 3083
2021
Q4 		$2.33M Buy
2,371
+154
+7% +$197K ﹤0.01% 2651
2021
Q3 		$3.26M Buy
2,217
+637
+40% +$1.24M ﹤0.01% 2573
2021
Q2 		$3.35M Buy
1,580
+54
+4% +$122K ﹤0.01% 2548
2021
Q1 		$3.88M Buy
+1,526
New +$3.91M ﹤0.01% 2414

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Charles Schwab's BCAB Position: Q2 2024 in Review

Charles Schwab sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 2,391 shares — an estimated $411K sold.

Charles Schwab first reported a position in BCAB in Q1 2021 and held it in 13 quarters. The position peaked at $3.88M in Q1 2021. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Charles Schwab reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • Charles Schwab sold 2,391 BioAtla shares in Q2 2024, an estimated $411K.
  • Charles Schwab first reported a position in BioAtla in Q1 2021 and held it in 13 quarters.
  • Charles Schwab's BioAtla position peaked at $3.88M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.